Transdermal Dual-Therapy of Metformin and Trans-Resveratrol Nanocochleates with Synergistic Anticancer Effects
Mohamed El-Melegy – Assistant Lecturer, Faculty of pharmacy, Alexandria University; Radwa Mehanna – Professor, Faculty of Medicine, Alexandria University; Ahmed Gaballah – Associate Professor, Medical Research Institute, Alexandria University; Amal El-Kamel – Professor, Faculty of pharmacy, Alexandria University
Assistant Lecturer Faculty of Pharmacy, Alexandria University Alexandria, Al Iskandariyah, Egypt
Introduction: Nanocochleates are emerging lipid-based nanocarriers that offer high stability, sustained drug release, biodegradability, and enhanced bioavailability. They can improve drug safety and efficacy while minimizing adverse effects particularly in cancers where regional, or controlled systemic therapies are required. Herein, we develop metformin (MET)-bridged (1) and trans-resveratrol (trans-RSV)-loaded nanocochleates (2) for transdermal delivery. The work explores a dual-therapy nanocochleate platform to enhance transdermal skin permeation and synergistically augment anticancer activity.
Learning Objectives:
Nanocochleates exhibited stable, nanosized structures with favourable physicochemical characteristics.
Nanocochleates demonstrated significantly enhanced transdermal permeation of Resveratrol and Metformin
Nanocochleates dual therapy showed pronounced apoptosis and synergistic anticancer activity
